1
|
Kim H, Lee J, Lim D, Kim Y, Park S, Ahn S, Kim I, Im J, Chung J, Kim J, Kim I, Yoon H, Suh C. PD-0243 Pediatric diffuse intrinsic pontine glioma treated with radiotherapy: the National multicenter study. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02798-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Lee B, Cho J, Chang J, Kang S, Kim E, Moon J, Ahn S, Park Y, Suh C, Yoon H. PD-0246 The role of adjuvant RT in craniopharyngioma in 2021 WHO new classification of CNS tumor era. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02801-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Yi J, Kim W, Kim S, Yoon D, Suh C, Lee WS, Yang D, Jo JC, Koh Y, Lee JO, Kim B, Lim S, Heo M, Sohn B, Choi Y, Park J, Kim H, Lee S, Oh S. 261P Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
4
|
Hohloch K, Windemuth-Kieselbach C, Zinzani PL, Cacchione R, Jurczak W, Suh C, Trümper L, Scholz CW. Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry. Ann Hematol 2020; 99:1073-1079. [PMID: 32125469 PMCID: PMC7196943 DOI: 10.1007/s00277-020-03956-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Accepted: 02/06/2020] [Indexed: 11/23/2022]
Abstract
To assess the efficacy of radioimmunotherapy (RIT) with 90yttrium-ibrutinib-tiuxetan (90Y-IT) in mantle cell lymphoma, data from 90 patients registered in the RIT Network with a median follow-up (FU) of 5.5 years after RIT were evaluated. 90Y-IT was given as first-line therapy in 45 (50%) and for relapse in 45 (50%) patients. Most patients received 90Y-IT as consolidation after chemoimmunotherapy in first line (98%) and in relapse (53%). As a first-line treatment, 30 patients (pts.) (67%) achieved CR, 10 pts. (22%) PR%. and 1 pt. (2%) PD, and for 4 pts. (9%), no response data was available. At relapse, CR was achieved in 17 pts. (38%), PR in 6 pts. (13%), SD in 2 pts. (4%), and 6 pts. (13%) had PD, while the response was not documented for 14 pts. (31%). After a median FU of 5.5 years, median PFS for all patients was 2.11 (95% CI, 1.03–2.32) years, and median OS was 4.05 (95% CI, 2.79–7.21) years. Eleven pts. (12.2%) developed second malignancy. In conclusion, this is the largest report of MCL pts. treated with 90Y-IT to date. 90Y-IT was most often used as consolidation after first- and second-line chemotherapy and may improve the results achieved using chemoimmunotherapy alone. However, the results are less encouraging compared to treatment with small molecules such as ibrutinib.
Collapse
Affiliation(s)
- Karin Hohloch
- Department of Hematology and Oncology, Kantonsspital Graubünden, Chur, Switzerland. .,Department of Hematology and Oncology, Georg August University, Goettingen, Germany.
| | | | - Pier Luigi Zinzani
- Institute of Hematology "Seràgnoli", Università di Bologna, Bologna, Italy
| | - Roberto Cacchione
- Médica e Investigaciones Clínical, "Norberto Quirno", CEMIC, Centro de Educación, Buenos Aires, Argentina
| | - Wojciech Jurczak
- Department of Haematology, Jagiellonian University, Cracow, Poland
| | - C Suh
- Asan Medical Center, Department of Internal Medicine, Division of Oncology, University of Ulsan College of Medicine, Seoul, South Korea
| | - Lorenz Trümper
- Department of Hematology and Oncology, Georg August University, Goettingen, Germany
| | - Christian W Scholz
- Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany
| |
Collapse
|
5
|
Yi J, Kim W, Kim S, Yoon D, Suh C, Chang M, Yang D, Jo JC, Hyun S, Eom HS, Lee JO, Kwon J, Han S, Lee SS, Kwak JY, Kim S. Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz446.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Jeong S, Kim S, Hong J, Park Y, Kang H, Koh Y, Lee G, Lee W, Yang D, Do Y, Kim M, Yoo K, Yun W, Yi J, Jo J, Eom H, Kwak J, Shin H, Park B, Lee J, Yi S, Kwon J, Oh S, Kim H, Sohn B, Won J, Hong D, Lee H, Suh C, Kim W. A PROSPECTIVE REGISTRY STUDY OF PEG-G-CSF PROPHYLAXIS FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (CISL 1403). Hematol Oncol 2019. [DOI: 10.1002/hon.122_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- S. Jeong
- Department of Hematology-Oncology; Ajou University Hospital; Suwon Republic of Korea
| | - S. Kim
- Department of Medicine; Samsung Medical Center; Seoul Republic of Korea
| | - J. Hong
- Department of Oncology; Asan Medical Center; Seoul Republic of Korea
| | - Y. Park
- Department of Internal Medicine; Korea University Anam Hospital; Seoul Republic of Korea
| | - H. Kang
- Department of Internal Medicine; Korea Cancer Center Hospital Korea Institute of Radiological and Medical Sciences; Seoul Republic of Korea
| | - Y. Koh
- Department fo Internal Medicine; Seoul National University Hospital; Seoul Republic of Korea
| | - G. Lee
- Deparmtment of Internal Medicine; Gyeongsang National University Hospital; Jinju Republic of Korea
| | - W. Lee
- Department of Internal Medicine; Inje University Busan Paik Hospital; Busan Republic of Korea
| | - D. Yang
- Department of Internal Medicine; Chonnam National University Hwasun Hospital; Hwasun Republic of Korea
| | - Y. Do
- Department of Medicine; Dongsan Medical Center; Daegu Republic of Korea
| | - M. Kim
- Department of Medicine; Yeungnam University College of Medicine; Gaegu Republic of Korea
| | - K. Yoo
- Department of Internal Medicine; Gachon University Gil Medical Center, Gachon University College of Medicine; Incheon Republic of Korea
| | - W. Yun
- Department fo Internal Medicine; Chongnam National University Hospital; Daejeon Republic of Korea
| | - J. Yi
- Department of Interanl Medicine; Chung-Ang University Hospital; Seoul Republic of Korea
| | - J. Jo
- Department of Hematology-Oncology; Ulsan University Hospital, University of Ulsan College of Medicine; Ulsan Republic of Korea
| | - H. Eom
- Hematology-oncology clinic; National Cancer Center; Goyang Republic of Korea
| | - J. Kwak
- Department of Internal Medicine; Chonbuk National University Medical School; Jeonju Republic of Korea
| | - H. Shin
- Department of Internal Medicine; Pusan National University Hospital; Busan Republic of Korea
| | - B. Park
- Department of Interanl Medicine; Hanyang University College of Medicine; Seoul Republic of Korea
| | - J. Lee
- Department of Hematology-oncology; Wonju Severance Christian Hospital; Wonju Republic of Korea
| | - S. Yi
- Deparment of Internal Medicine; Inje University Ilsan Hospital; Goyang Republic of Korea
| | - J. Kwon
- Department of Internal Medicine; Chungbuk National University Hospital; Cheongju Republic of Korea
| | - S. Oh
- Department of Internal Medicine; Dong-A University Medical Center; Busan Republic of Korea
| | - H. Kim
- Deparment of Interanl Medicine; Hallym University Sacred Heart Hospital; Anyang Republic of Korea
| | - B. Sohn
- Department of Internal Medicine; Inje University Sanggye Paik Hospital; Seoul Republic of Korea
| | - J. Won
- Department of Internal Medicine; Soonchunhyang University Hospital, Soonchunhyang University College of Medicine; Seoul Republic of Korea
| | - D. Hong
- Department of Internal Medicine; Soonchunhyang University Bucheon Hospital; Bucheon Republic of Korea
| | - H. Lee
- Department of Internal Medicine; Kosin University Gospel Hospital; Busan Republic of Korea
| | - C. Suh
- Department of Oncology; Asan Medical Center; Seoul Republic of Korea
| | - W. Kim
- Department of Medicine; Samsung Medical Center; Seoul Republic of Korea
| |
Collapse
|
7
|
Kim S, Jo J, Yoon D, Hong J, Do Y, Yea J, Lim S, Shin H, Lee H, Yhim H, Yi J, Choi Y, Kim M, Yang D, Lee W, Kang H, Suh C, Kim W. RANDOMIZED PHASE II STUDY OF CHOP VS. FRACTIONATED ICED IN TRANSPLANT-ELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA: INTERIM RESULTS OF CISL1504. Hematol Oncol 2019. [DOI: 10.1002/hon.146_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Kim
- Medicine; Samsung Medical Cneter; Seoul Republic of Korea
| | - J. Jo
- Internal Medicine; Ulsan University Hospital; Ulsan Republic of Korea
| | - D. Yoon
- Oncology; Asan Medical Center; Seoul Republic of Korea
| | - J. Hong
- Oncology; Asan Medical Center; Seoul Republic of Korea
| | - Y. Do
- Internal Medicine; Dongsan Medical Center; Daegu Republic of Korea
| | - J. Yea
- Radiation oncology; Yeungnam University Medical Center; Daegu Republic of Korea
| | - S. Lim
- Internal Medicine; Inje University College of Medicine, Haeundae Paik Hospital; Busan Republic of Korea
| | - H. Shin
- Internal Medicine; Pusan National University Hospital; Busan Republic of Korea
| | - H. Lee
- Internal Medicine; Konkuk University Medical Center; Seoul Republic of Korea
| | - H. Yhim
- Medicine; Chonbuk National University Medical School; Jeonju Republic of Korea
| | - J. Yi
- Internal Medicine; Chung-Ang University Hospital; Seoul Republic of Korea
| | - Y. Choi
- Internal Medicine; Chungnam National University; Daejon Republic of Korea
| | - M. Kim
- Internal Medicine; Yeungnam University College of Medicine; Daegu Republic of Korea
| | - D. Yang
- Internal Medicine; Chonnam National University Hwasun Hospital; Hwasun Republic of Korea
| | - W. Lee
- Internal Medicine; Inje University Busan Hospital; Busan Republic of Korea
| | - H. Kang
- Internal Medicine; Korea Cancer Center Hospital; Seoul Republic of Korea
| | - C. Suh
- Oncology; Asan Medical Center; Seoul Republic of Korea
| | - W. Kim
- Medicine; Samsung Medical Cneter; Seoul Republic of Korea
| |
Collapse
|
8
|
Lee J, Oh D, Choi B, Eom K, Lee J, Kim J, Lee S, Suh Y, Suh C. EP-1264 Patterns of care for orbital MALToma in Korea throughout 2016: a multicenter cross-sectional study. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31684-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Choi J, Kim S, Chang J, Park S, Suh C. PO-0738 Extent of resection is potent prognostic factor next to molecular subtype in low-grade glioma. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31158-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Sohn B, Lim SN, Kim J, Yoon D, Kim S, Huh J, Park SE, Yuh Y, Suh C. The β2-microgloulin is associated with the prognosis in patients with peripheral t-cell lymphoma, not otherwise specified. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy286.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Lim SN, Sohn B, Shin HJ, Suh C, Kim W, Lee W, Kim J. Combination of chemotherapy and radiation improve the prognosis of primary diffuse large B-cell lymphoma of the tonsil. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy286.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Kim E, Youm H, Kim S, Lee J, Suh C, Kim S. The effects of mouse aging on in vitro ovarian follicle development and oocyte competence. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Lim SH, Hong JY, Lim ST, Hong H, Arnoud J, Zhao W, Yoon DH, Tang T, Cho J, Park S, Ko YH, Kim SJ, Suh C, Lin T, Kim WS. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol 2018; 28:2199-2205. [PMID: 28911074 DOI: 10.1093/annonc/mdx316] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Background Current standard treatment, including non-anthracycline-based chemotherapy and optimal combining of radiotherapy, has dramatically improved outcomes of patients with extranodal natural killer/T-cell lymphoma (ENKTL) during the last decade. This study was conducted to investigate the clinical outcome of ENKTL patients with relapsed or progressive disease after initial current standard therapy. Patients and methods We retrospectively reviewed patients diagnosed with ENKTL at six centers in four countries (China, France, Singapore, and South Korea) from 1997 to 2015 and analyzed 179 patients who had relapsed or progressed after initial current standard therapy. Results After a median follow-up of 58.6 months (range 27.9-89.2), the median second progression-free survival (PFS) was 4.1 months [95% confidence interval (CI) 3.04-5.16] and overall survival (OS) was 6.4 months (95% CI 4.36-8.51). Multivariate Cox-regression analysis revealed that elevated lactate dehydrogenase, multiple extranodal sites (≥2), and presence of B symptoms were associated with inferior OS (P < 0.05). OS and PFS were significantly different according to both prognostic index of natural killer lymphoma (PINK) and PINK-E (Epstein-Barr virus) models. Salvage chemotherapy with l-asparaginase (l-Asp)-based regimens showed a significantly better clinical benefit to response rate and PFS, although it did not lead to OS improvement. First use of l-Asp in the salvage setting and l-Asp rechallenge at least 6 months after initial treatment were the best candidates for salvage l-Asp containing chemotherapy. Conclusions Most patients with relapsed or refractory ENKTL had poor prognosis with short survival. Further studies are warranted to determine the optimal treatment of patients with relapsed or refractory ENKTL.
Collapse
Affiliation(s)
- S H Lim
- Division of Hematology-Oncology, Department of Internal Medicine, Soon Chun Hyang University, Bucheon Hospital, Bucheon-si.,Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul
| | - J Y Hong
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - S T Lim
- Division of Medical Oncology, National University Cancer Institute, Singapore
| | - H Hong
- State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
| | - J Arnoud
- Department of Hematology, CHU, Limoges, France
| | - W Zhao
- State Key Laboratory of Medical Genomics, Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - D H Yoon
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - T Tang
- Division of Medical Oncology, National University Cancer Institute, Singapore
| | - J Cho
- Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul
| | - S Park
- Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul
| | - Y H Ko
- Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - S J Kim
- Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul
| | - C Suh
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - T Lin
- State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
| | - W S Kim
- Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul
| |
Collapse
|
14
|
Kwong Y, Kim S, Tse E, Oh S, Kwak J, Eom H, Do Y, Mun Y, Lee S, Shin H, Suh C, Chuang S, Lee Y, Lim S, Izutsu K, Suzuki R, Relander T, d’Amore F, Schmitz N, Jaccard A, Kim W. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol 2018; 29:256-263. [DOI: 10.1093/annonc/mdx684] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
15
|
Brady J, Binkley M, Hajj C, Chelius M, Chau K, Levis M, Choi S, Suh C, Hardy S, Constine L, Krog Vistisen A, Bratman S, Reinartz G, Eich H, Oguchi M, Kirova Y, Ng A, Warbey V, Barrington S, El-Galaly T, Filippi A, Ricardi U, Yahalom J, Hoppe R, Mikhaeel N. OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF 18
F-FDG PET-CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_10] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J.L. Brady
- Department of Clinical Oncology; Guy's and St Thomas' Hospital; London UK
| | - M.S. Binkley
- Department of Radiation Oncology; Stanford Cancer Institute and Stanford University School of Medicine; Stanford USA
| | - C. Hajj
- Department of Radiation Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - M.R. Chelius
- Department of Radiation Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - K.W. Chau
- Department of Radiation Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Levis
- Department of Oncology; University of Torino; Torino Italy
| | - S. Choi
- Department of Radiation Oncology; Yonsei University College of Medicine; Seoul Republic of Korea
| | - C. Suh
- Department of Radiation Oncology; Yonsei University College of Medicine; Seoul Republic of Korea
| | - S.J. Hardy
- Department of Radiation Oncology; University of Rochester Medical Center; Rochester USA
| | - L.S. Constine
- Department of Radiation Oncology; University of Rochester Medical Center; Rochester USA
| | - A. Krog Vistisen
- Department of Haematology; Aalborg University Hospital; Aalborg Denmark
| | - S.V. Bratman
- Department of Radiation Oncology; Princess Margaret Cancer Center and University of Toronto; Toronto Canada
| | - G. Reinartz
- Department of Radiotherapy; University Hospital Muenster; Muenster Germany
| | - H.T. Eich
- Department of Radiotherapy; University Hospital Muenster; Muenster Germany
| | - M. Oguchi
- Department of Radiation Oncology; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan
| | - Y.M. Kirova
- Department of Radiation Oncology; Institut Curie; Paris France
| | - A.K. Ng
- Department of Radiation Oncology, Dana-Farber Cancer Institute; Harvard Medical School; Boston USA
| | - V.S. Warbey
- PET Imaging Centre at St Thomas' Hospital; King's College London; London UK
| | - S.F. Barrington
- PET Imaging Centre at St Thomas' Hospital; King's College London; London UK
| | - T.C. El-Galaly
- Department of Haematology; Aalborg University Hospital; Aalborg Denmark
| | - A.R. Filippi
- Department of Oncology; University of Torino; Torino Italy
| | - U. Ricardi
- Department of Oncology; University of Torino; Torino Italy
| | - J. Yahalom
- Department of Radiation Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - R.T. Hoppe
- Department of Radiation Oncology; Stanford Cancer Institute and Stanford University School of Medicine; Stanford USA
| | - N.G. Mikhaeel
- Department of Clinical Oncology; Guy's and St Thomas' Hospital and King's Health Partners Academic Health Sciences Centre; London UK
| |
Collapse
|
16
|
Kang J, Hong J, Yoon D, Suh C. CLINICAL FEATURES AND SURVIVAL OUTCOMES ON LYMPHOPLASMACYTIC LYMPHOMA PATIENTS WITH NON-IGM PARAPROTEINEMIA COMPARED WITH IGM PARAPROTEINEMIA IN KOREA. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Kang
- Oncology, Asan Medical Center; University of Ulsan College of Medicine; Seoul Republic of Korea
| | - J. Hong
- Oncology, Asan Medical Center; University of Ulsan College of Medicine; Seoul Republic of Korea
| | - D. Yoon
- Oncology, Asan Medical Center; University of Ulsan College of Medicine; Seoul Republic of Korea
| | - C. Suh
- Oncology, Asan Medical Center; University of Ulsan College of Medicine; Seoul Republic of Korea
| |
Collapse
|
17
|
Park B, Kim W, Suh C, Yang D, Do Y, Jo J, Park Y. A PHASE II TRIAL OF BENDAMUSTINE, CARBOPLATIN AND DEXAMETHASONE (BCD) FOR REFRACTORY OR RELAPSED PERIPHERAL T-CELL LYMPHOMA (BENCART): A CONSORTIUM FOR IMPROVING SURVIVAL OF LYMPHOMA (CISL) TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_161] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- B. Park
- Division of Hematology/Oncology, Department of Internal Medicine; Hanyang University College of Medicine; Seoul Republic of Korea
| | - W. Kim
- Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Republic of Korea
| | - C. Suh
- Department of Internal Medicine, Asan Medical Center; University of Ulsan College of Medicine; Seoul Republic of Korea
| | - D. Yang
- Department of Hemato-Oncology; Chonnam National University Hwasun Hospital; Jeollanam-do Republic of Korea
| | - Y. Do
- Department of Hemato-Oncology; Keimyung University Dongsan Medical Center; Daegu Republic of Korea
| | - J. Jo
- Division of Hematology and Cellular Therapy; Ulsan University Hospital, University of Ulsan College of Medicine; Ulsan Republic of Korea
| | - Y. Park
- Division of Hematology/Oncology, Department of Internal Medicine; Korea University College of Medicine; Seoul Republic of Korea
| |
Collapse
|
18
|
Roh T, Kim E, Kang S, Cho J, Suh C, Kim S, Chang J. P09.45 Impact of extent of resection for long-term survival in patients with glioblastoma. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Kim H, Kim S, Chang J, Suh C, Cho J. P10.07 Prognostic factors of gliosarcoma - a single institution study. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Kang Y, Seo S, Hong J, Yoon D, Kim S, Park J, Huh J, Lee SW, Ryu JS, Suh C. Proposal of improved prognostic index for patients with extranodal natural killer/T cell lymphoma treated with non-anthracycline based treatment. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Kim S, Shin DY, Kim J, Yoon D, Lee W, Lee H, Do Y, Kang H, Eom H, Ko Y, Lee S, Yoo H, Hong M, Suh C, Kim W. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Ann Oncol 2016; 27:712-718. [DOI: 10.1093/annonc/mdv624] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
22
|
Cho Y, Kim K, Keum K, Suh C, Kim G, Kim Y. OC-0538: Tumor-related leukocytosis associated with poor radiation response and outcome in cervical cancer. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31788-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
23
|
Lee WJ, Won KH, Won CH, Chang SE, Choi JH, Moon KC, Park CS, Huh J, Suh C, Lee MW. Secondary cutaneous lymphoma: comparative clinical features and survival outcome analysis of 106 cases according to lymphoma cell lineage. Br J Dermatol 2015; 173:134-45. [PMID: 25556641 DOI: 10.1111/bjd.13582] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/27/2014] [Indexed: 11/26/2022]
Abstract
BACKGROUND The relative frequency, clinical features and survival outcomes of secondary cutaneous lymphoma remain poorly understood. OBJECTIVES To determine the clinical characteristics and survival outcomes of secondary cutaneous lymphoma. MATERIALS AND METHODS The present retrospective cohort study included all 106 patients who presented with secondary cutaneous lymphoma. Patient medical records were reviewed to determine the clinical features, survival outcomes and prognostic factors. Survival outcomes were analysed by using the Kaplan-Meier method and comparisons between lymphoma cell lineages [T or natural killer (T-/NK)-cell vs. B-cell lymphoma] were performed using the log-rank test. RESULTS Secondary cutaneous lymphomas consisted of mature T-/NK-cell lymphomas (56%), mature B-cell lymphomas (35%), immature haematopoietic malignancies (8%) and Hodgkin lymphoma (1%). The T-/NK-cell lineage lymphoma cases were more likely to have multiple and disseminated skin lesions than the B-cell lineage lymphoma cases. The lymphoma cell lineage did not significantly influence survival outcomes. Patients who showed cutaneous involvement within 6 months of the initial diagnosis of primary disease had a poorer overall survival (OS) outcome than patients who developed cutaneous dissemination 6 or more months after the initial diagnosis (P < 0.001). Patients with disseminated skin lesions had a poorer OS than patients with localized skin lesions (P = 0.028). The two lymphoma cell lineages differed in terms of prognostic factors that influenced survival. CONCLUSIONS Skin lesion characteristics such as time point of appearance and extent affect the survival outcomes of secondary cutaneous lymphoma. Cell lineage did not influence survival outcomes but the two lineages are associated with different prognostic factors.
Collapse
Affiliation(s)
- W J Lee
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong Songpagu, Seoul, 138-736, Korea
| | - K H Won
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong Songpagu, Seoul, 138-736, Korea
| | - C H Won
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong Songpagu, Seoul, 138-736, Korea
| | - S E Chang
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong Songpagu, Seoul, 138-736, Korea
| | - J H Choi
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong Songpagu, Seoul, 138-736, Korea
| | - K C Moon
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong Songpagu, Seoul, 138-736, Korea
| | - C-S Park
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong Songpagu, Seoul, 138-736, Korea
| | - J Huh
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong Songpagu, Seoul, 138-736, Korea
| | - C Suh
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong Songpagu, Seoul, 138-736, Korea
| | - M W Lee
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnapdong Songpagu, Seoul, 138-736, Korea
| |
Collapse
|
24
|
Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, Jo J, Jung SH, Hong ME, Yoon H, Ko YH, Kim SJ, Kim WS. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol 2015; 26:548-55. [PMID: 25475080 DOI: 10.1093/annonc/mdu556] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is defined only in adults older than 50 years. However, EBV-positive DLBCL can affect younger patients. We investigated the prevalence, clinical characteristics and survival outcomes of EBV-positive DLBCL in young adults. PATIENTS AND METHODS We analyzed patients with de novo DLBCL who were registered in the Samsung Medical Center (SMC) retrospective lymphoma cohort and prospective SMC Lymphoma Cohort Study I (ClinicalTrials.gov: NCT00822731). RESULTS A total of 571 cases were included in the analysis. The prevalence of EBV positivity was 6.7% (13/195) and 9.3% (35/376) in the young group (≤50 years) and in the elderly group (>50 years), respectively. EBV status was closely associated with unique unfavorable clinical characteristics [older age, more advanced stage, two or more sites of extranodal involvement, higher International Prognostic Index (IPI), and age-adjusted IPI risk] only in the elderly group. Poor prognostic impact of EBV positivity on overall survival was observed only in the elderly group [hazard ratio (HR) 2.86; 95% confidence interval (CI) 1.83-4.47; P < 0.001], but not in the young group (HR 1.17; 95% CI 0.35-3.89; P = 0.801). CONCLUSION A substantial proportion of EBV-positive DLBCL of the elderly can occur in young adults. EBV positivity of DLBCL in young adults was not associated with unfavorable clinical characteristics or worse outcomes. We suggest that EBV-positive DLBCL should not be confined only in the elderly and 'EBV-positive DLBCL in young adults' needs to be considered as a clinically distinct disease entity. ClinicalTrials.gov: NCT02060435.
Collapse
Affiliation(s)
- J Y Hong
- Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul
| | | | | | - J Huh
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul
| | - I-G Do
- Department of Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea
| | - I Sohn
- Department of Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea
| | - J Jo
- Department of Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea
| | - S-H Jung
- Department of Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea Department of Biostatistics and Bioinformatics, Duke University, Durham, USA
| | | | | | | | - S J Kim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - W S Kim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
25
|
Seo S, Yoo C, Yoon D, Park C, Huh J, Suh C. Clinical Features and Outcomes of Human Immunodeficiency Virus (Hiv)-Negative Patients with Multicentric Castleman'S Disease. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu339.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Noh J, Kim K, Park W, Suh C, Huh S, Choi D, Kim Y, Keum K. Prognostic Significance of Internal Mammary Node Involvement in Patients With Clinical Stage IIIC Breast Cancer Who Received Neoadjuvant Chemotherapy, Surgery, and Radiation Therapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
27
|
Lee J, Kim K, Cho J, Suh C. The Role of Radiation Therapy in Localized Nongastric and Nonorbital Mucosa-Associated Lymphoid Tissue Lymphoma. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1987] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
28
|
Park JH, Yoon DH, Kim DY, Kim S, Seo S, Jeong Y, Lee SW, Park CS, Huh J, Suh C. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab. Ann Hematol 2014; 93:1755-64. [PMID: 25027115 DOI: 10.1007/s00277-014-2115-z] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Accepted: 05/15/2014] [Indexed: 12/22/2022]
Abstract
Although the International Prognostic Index (IPI) is considered as the current standard prognostication system for diffuse large B-cell lymphoma (DLBCL), prognostic heterogeneity is suggested to exist among the patients within the same IPI risk group. Hence, we investigated the pattern of distribution and prognostic impact of five IPI factors within the same IPI score. We retrospectively reviewed the medical records of 387 patients newly diagnosed as pathologically proven DLBCL between February 2002 and February 2010. We classified patients to IPI risk scores and categorized them according to the combinations of IPI. Then, we explored the frequency of five IPI factors and analyzed the correlation between these subgroups and efficacy outcomes: complete response (CR), event-free survival (EFS), and overall survival (OS). Survival estimates by IPI score in this cohort corresponded to the classic IPI. Elevated serum level of lactate dehydrogenase (LDH) was the most prevalently distributed factor throughout the scores, and patients with elevated serum level of LDH tended to have lower CR, inferior EFS, and/or OS irrespective of IPI scores. Particularly, among the subgroups of IPI score of 2, elevated serum level of LDH was significantly associated with inferior CR (73.1 vs 95.2 %), 3-year EFS (57 vs 87 %), and 3-year OS (58 vs 82 %). In addition, the higher serum level of LDH, particularly above 2,000 IU/L, was significantly correlated with the inferior survival outcomes (3-year EFS 78.0 vs 58.5 vs 45.5 vs 20.0 %, 3-year OS 86.0 vs 66.2 vs 58.2 vs 40.0 %). In conclusion, among five factors of IPI, elevated serum level of LDH seems to be the most frequently distributed and, more importantly, the most relevant IPI factor with the highest prognostic impact. These findings still warrant further validation in larger cohorts.
Collapse
Affiliation(s)
- J H Park
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Lee J, Suh C, Lee H, Yoon J, Park K, Chung Y, Choi W, Kim J. EP-1472: Reducing effectiveness of hair loss by additional lead block for electron treatment of eyelid lesion patients. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31590-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
30
|
Lee J, Kim K, Cho J, Suh C. PO-0650: The role of radiotherapy in localized nongastric and nonorbital mucosa-associated lymphoid tissue lymphoma. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30768-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Jin S, Chae SY, Chang SE, Suh C, Lee SW, Ryu JS. A case of xanthoma disseminatum: evaluation and monitoring by 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Br J Dermatol 2013; 170:1177-81. [PMID: 24329687 DOI: 10.1111/bjd.12789] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/10/2013] [Indexed: 12/27/2022]
Abstract
Xanthoma disseminatum (XD) is a rare benign histiocytic disorder with extensive mucocutaneous xanthomas that often involves other sites such as the central nervous system (CNS), respiratory tract and abdominal organs. Evaluation of the extent of disease is important because lesions in critical locations may increase morbidity and mortality. However, there are no well-established tools for the evaluation and monitoring of XD. Here, we report a case of XD in a 21-year-old male patient showing skin, mucous membrane, CNS and internal organ involvement. In this case, (18) F-fluorodeoxyglucose positron emission tomography/computed tomography was useful in detecting the extent of the disease and in estimating the therapeutic response.
Collapse
Affiliation(s)
- S Jin
- Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea
| | | | | | | | | | | |
Collapse
|
32
|
Jeongshim L, Lee I, Chang J, Suh C. Re-irradiation for Recurrent Gliomas: Treatment Outcomes and Prognostic Factors. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
33
|
Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, Lee DH, Pyo H, Song SY, Jung SH, Jo JS, Jo J, Sohn HJ, Suh C, Lee JS, Kim SW, Park K. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol 2013; 24:2088-92. [PMID: 23592701 DOI: 10.1093/annonc/mdt140] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND We compared late thoracic radiotherapy (TRT) with early TRT in the treatment of limited-disease small-cell lung cancer (LD-SCLC). PATIENTS AND METHODS Patients with LD-SCLC received four cycles of etoposide plus cisplatin every 21 days. Patients were randomly assigned to receive either TRT administered concurrently with the first cycle (early TRT) or the third cycle (late TRT) of chemotherapy. The primary end point was complete response rate. RESULTS Two hundred twenty-two patients were randomly assigned.Late TRT was not inferior to early TRT in terms of the complete response rate (early v late; 36.0% v 38.0%). Other efficacy measures including overall survival [median, 24.1 v 26.8 months;hazard ratio (HR) 0.93; 95% CI = 0.67–1.29] and progression free survival (median, 12.4 v 11.2 months; HR 1.09; 95%CI = 0.80–1.48) were not different between two arms. No statistical difference was noted in the pattern of treatment failures.However, neutropenic fever occurred more commonly in the early TRT arm than the late TRT arm (21.6% v 10.2%; P = 0.02) [corrected]. CONCLUSION In LD-SCLC treatment, TRT starting in the third cycle of chemotherapy seemed to be noninferior to early TRT, and had a more favorable profile with regard to neutropenic fever.
Collapse
Affiliation(s)
- J-M Sun
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Kim JY, Lee SW, Lee JH, Suh C, Yoon DH, Lee BJ, Huh J, Choi EK, Kim JH, Song SY, Yoon SM, Kim YS, Kim SS, Park JH, Shin HS, Chang SK, Ahn SD. Stage IE/IIE extranodal NK/T-cell lymphoma arising in the nasal cavity: analysis of CT findings and their prognostic value. Clin Radiol 2013; 68:e384-90. [PMID: 23535315 DOI: 10.1016/j.crad.2012.11.023] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Revised: 11/08/2012] [Accepted: 11/12/2012] [Indexed: 10/27/2022]
Abstract
AIM To investigate the computed tomography (CT) findings in patients with stage IE/IIE extranodal natural killer/T-cell lymphoma (ENKTL) arising in the nasal cavity and to evaluate whether imaging findings revealed by CT have prognostic value. MATERIALS AND METHODS The CT findings of 62 patients diagnosed with IE/IIE ENKTL arising in the nasal cavity were retrospectively reviewed. Imaging findings were investigated, and evaluated imaging findings were analysed for the prognostic value of overall survival (OS) and disease-free survival (DFS). RESULTS Of the 62 patients, 21 (34%) presented with a superficial infiltrative, 38 (61%) with a mass forming, and three (5%) with a combined pattern. Of all imaging findings, local invasiveness (n = 26, 42%), including bony destruction, erosion, or soft-tissue involvement, was the only independent prognostic factor for OS [p = 0.008; hazard ratio (HR): 3.85; 95% confidence intervals (CI): 1.42-10.44] and DFS (p = 0.001; HR: 4.25; 95% CI: 1.72-10.47). In a subgroup analysis of 36 cases with no local invasiveness, a superficial infiltrative pattern in one nasal cavity was a positive prognostic factor for OS (p = 0.028) and DFS (p = 0.008). CONCLUSION Imaging findings at CT provided clinically useful predictions for treatment outcomes. Local invasiveness revealed by CT findings was a strong prognostic factor for poor OS and DFS. In addition, in patients with no local invasiveness, a superficial infiltrative pattern in one nasal cavity predicted favourable OS and DFS.
Collapse
Affiliation(s)
- J Y Kim
- Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Kim J, Lee S, Suh C, Huh J, Kim J, Lee B, Choi E, Shin H, Ahn S. Predictive Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography After Frontline Treatment and Consolidative Treatment in Patients With Extranodal NK/T-cell Lymphoma. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
36
|
Kim Y, Suh Y, Suh C, Lee J, Cha J, Cho J. The Role of Radiation Therapy in the Management of POEMS Syndrome. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
37
|
Kim J, Lee S, Suh C, Huh J, Lee B, Choi E, Shin H, Ahn S. Stage IE/IIE Extranodal NK/T-cell Lymphoma Arising From the Nasal Cavity: Investigation of Computed Tomography Findings and Its Prognostic Values. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
Sun JM, Kim SW, Ahn MJ, Ahn J, Lee D, Ahn Y, Pyo H, Choi E, Song S, Lee SH, Suh C, Lee J, Park K. Concurrent Thoracic Radiotherapy (TRT) with Either the First Cycle or the Third Cycle of Cisplatin and Etoposide Chemotherapy to Determine the Optimal Timing of TRT for Limited-Disease Small-Cell Lung Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)31998-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
39
|
Kim W, Ando K, Niitsu N, Ogura M, Takahashi N, Uike N, Eom HS, Chae Y, Tobinai K, Terauchi T, Tateishi U, Tatsumi M, Suh C. A Multicenter Phase II Study of Bendamustine with Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32234-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
40
|
Moon SM, Lee SO, Choi SH, Kim YS, Woo JH, Yoon DH, Suh C, Kim DY, Lee JH, Lee JH, Lee KH, Kim SH. Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. Transpl Infect Dis 2012; 15:104-9. [PMID: 22823749 DOI: 10.1111/j.1399-3062.2012.00765.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2011] [Revised: 01/25/2012] [Accepted: 05/16/2012] [Indexed: 02/04/2023]
Abstract
A total of 244 patients including 100 (41%) autologous hematopoietic stem cell transplant (HCT) recipients and 144 (59%) allogeneic HCT recipients were enrolled over a 28-month period. During the study period, no prophylaxis for latent tuberculosis (TB) infection was administrated. Of these, 201 (82%) had Bacillus Calmette-Guérin (BCG) scars or prior histories of BCG vaccination. The tuberculin skin test (TST) and the QuantiFERON-TB Gold In-Tube (QFT-GIT) test were performed simultaneously in all 244 patients. TST indurations were ≥ 5 mm in 39 of these patients (15%), and in 25 (10%) indurations were ≥ 10 mm. In addition, 40 (16%) had positive QFT-GIT outcomes, and 34 (14%) indeterminate outcomes. If the 34 patients with indeterminate QFT-GIT results were excluded from the overall agreement analysis, the agreement between the TST results (induration size ≥ 5 mm) and the QFT-GIT results in the 210 patients with clear QFT results was poor (κ = 0.08, 95% confidence interval [CI] -0.06 to 0.24), as it was for the patients with indurations ≥ 10 mm (κ = 0.15, 95% CI -0.004 to 0.31). During follow up, 2 patients developed TB after HCT. The incidence of TB in the patients with positive QFT-GIT outcomes was 2.80 per 100 person-years (95% CI 0.07-15.81), whereas among those with positive TST (≥ 5 mm) results, it was 0 per 100 person-years (95% CI 0-8.00). However, this finding should be cautiously interpreted because of the relatively short follow up and the fact that the sample size of the study cohort did not have adequate power. In conclusion, our data show that, although the frequencies of positive outcomes in the 2 TB screening tests were similar, the overall agreement between the TST and the QFT-GIT test was poor, regardless of BCG vaccination history.
Collapse
Affiliation(s)
- S M Moon
- Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Affiliation(s)
- J Huh
- Departments of Pathology. mailto:
| | - C Suh
- Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| |
Collapse
|
42
|
Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012; 77:556-60. [PMID: 22677429 DOI: 10.1016/j.lungcan.2012.05.092] [Citation(s) in RCA: 259] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2012] [Revised: 04/30/2012] [Accepted: 05/06/2012] [Indexed: 11/27/2022]
Abstract
Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase inhibitors (TKIs). We prospectively evaluated the efficacy of EGFR TKI for metastatic brain tumors in NSCLC patients harboring EGFR mutation. This was an open-label, single-institution, phase II study. Patients diagnosed with NSCLC harboring EGFR mutation and measurable metastatic brain tumors were eligible. They received either erlotinib or gefitinib once a day. Out of total 28 patients enrolled, 23 patients (83%) showed a partial response (PR) and 3 patients (11%) did stable disease (SD), giving a disease control rate of 93%. Median progression free survival (PFS) and overall survival (OS) were 6.6 months (95% CI, 3.8-9.3 months) and 15.9 months (95% CI, 7.2-24.6 months), respectively. There was no difference in PFS and OS according to EGFR TKIs used. After discontinuation of the treatment, 14 patients (50%) received local therapy for metastatic brain tumors during their disease course, either whole brain radiotherapy or radiosurgery, giving a local therapy-free interval of 12.6 months (95% CI, 7.6-17.6 months). EGFR TKI therapy might be the treatment of choice for metastatic brain tumors in NSCLC patients harboring an activating EGFR mutation.
Collapse
Affiliation(s)
- S J Park
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea
| | | | | | | | | | | | | |
Collapse
|
43
|
Shin SY, Jang S, Park CJ, Chi HS, Lee JH, Lee JH, Lee KH, Suh C, Lim SE, Seo EJ. Application of an immune-magnetic cell sorting method for CD138-positive plasma cells in FISH analysis of multiple myeloma. Int J Lab Hematol 2012; 34:541-6. [PMID: 22672327 DOI: 10.1111/j.1751-553x.2012.01433.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Interphase fluorescence in situ hybridization (FISH) analysis of multiple myeloma (MM) may indiscriminately count signals of nonplasma cells, thus decreasing specificity and sensitivity. We aimed to evaluate the usefulness of an immune-magnetic sorting method for plasma cells in FISH analysis of MM and define optimal sample preparation conditions. METHODS Plasma cells were purified using EasySep(®) CD138 Positive Selection Cocktail and Magnetic Nanoparticles (Invitrogen). We compared FISH results with and without plasma cell purification for three sample preparation methods: direct harvest, 24-h culture, and 96-h culture with interleukin-4 in five newly diagnosed MM patients. Archived fixed bone marrow cells of 17 MM patients were also studied. RESULTS The percentage of abnormal cells identified was significantly higher with plasma cell purification than without purification (median, 88.0%; range, 84.0-100.0%vs. 15.0%, 12.5-29.5%, respectively). The three sample preparation methods showed comparable results. Immune-magnetic sorting also significantly increased the percentage of abnormal cells identified in FISH analysis of archived fixed bone marrow cells (P < 0.001). CONCLUSIONS Immune-magnetic CD138-positive cell sorting significantly increased the percentage of abnormal cells identified in FISH analysis of MM samples for all sample preparation methods. This method could also be applied for retrospective FISH analysis of archived fixed bone marrow cells.
Collapse
Affiliation(s)
- S Y Shin
- Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Cho J, Kim Y, Suh C. EP-1028 THE ROLE OF RADIOTHERAPY IN THE MANAGEMENT OF POEMS SYNDROME. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71361-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Cha H, Cho J, Kim D, Suh C. EP-1019 FAVORABLE OUTCOMES OF ADJUVANT RADIOTHERAPY FOR INTRACRANIAL EPENDYMOMA; A SINGLE INSTITUTION EXPERIENCE. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71352-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
46
|
Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, Kim WS. Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol 2012; 23:2703-2707. [PMID: 22547542 DOI: 10.1093/annonc/mds096] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Clinical features and outcomes of extranodal natural killer/T-cell lymphoma (ENKL) arising from extranasal sites are not fully understood. The purpose of this study was to study the prognosis and treatment outcome of skin/soft tissue primary ENKL. PATIENTS AND METHODS This multicenter retrospective study included 48 patients with skin/soft tissue primary ENKL diagnosed from 1993 to 2010. RESULTS Patients with Ann Arbor stage I, T1-2N0M0 by International Society for Cutaneous Lymphomas-European Organization of Research and Treatment of Cancer TNM (tumour-node-metastasis) stage, International prognostic index score of 0-1, and a Korean prognostic index (KPI) score of 0-1 were associated with better survival. Four of five patients with T1-2N0M0 disease achieved complete response with radiation alone. In disseminated disease, only 6 of 13 patients responded to anthracycline-containing chemotherapy, and all the two patients receiving SMILE showed response. CONCLUSION In conclusion, we identified the prognostic value of KPI, and we suggest a treatment recommendation according to the TNM (tumour-node-metastasis) stage. Radiotherapy with/without chemotherapy seemed to be optimal in localized disease. In advanced stages, a more aggressive treatment regimen with newer agents should be sought.
Collapse
Affiliation(s)
- H K Ahn
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - C Suh
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - S S Chuang
- Department of Pathology, Chi-Mei Medical Center, Tainan and Taipei Medical University, Taipei, Taiwan
| | - J Suzumiya
- Department of Internal Medicine, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Y H Ko
- Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - S J Kim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - J R Huh
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul
| | - D H Yoon
- Department of Pathology, Chi-Mei Medical Center, Tainan and Taipei Medical University, Taipei, Taiwan
| | - S Y Oh
- Department of Internal Medicine, Dong-A University College of Medicine, Busan
| | - J S Kim
- Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul
| | - S I Lee
- Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea
| | - K W Park
- Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea
| | - P P Hsieh
- Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, and Center for General Education, Yuh-Ing Junior College of Health Care and Management, Kaohsiung, Taiwan
| | - S Nakamura
- Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya
| | - T Yoshino
- Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama
| | - K Ito
- Department of Dermatology, Niigata University Graduate School of Medicine, Niigata
| | - T Nagatani
- Department of Dermatology, Yokohama City University Medical Center, Yokohama
| | - K Oshimi
- Department of Hematology, Juntendo University, Tokyo
| | - R Suzuki
- Department of HSCT Data Management, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - W S Kim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
| |
Collapse
|
47
|
Furia GU, Kostelijk EH, Vergouw CG, Lee H, Lee S, Park D, Kang H, Lim C, Yang K, Lee S, Lim C, Park Y, Shin M, Yang K, Lee H, Beyhan Z, Fisch JD, Sher G, Keskintepe L, VerMilyea MD, Anthony JT, Graham JR, Tucker MJ, Tucker MJ, Freour T, Lattes S, Lammers J, Mansour W, Jean M, Barriere P, El Danasouri I, Gagsteiger F, Rinaldi L, Selman H, Antonova I, Milachich T, Valkova L, Shterev A, Barcroft J, Dayoub N, Thong J, Abdel Reda H, Khalaf Y, El Touky T, Cabry R, Brzakowski R, Lourdel E, Brasseur F, Copin H, Merviel P, Yamada M, Takanashi K, Hamatani T, Akutsu H, Fukunaga T, Inoue O, Ogawa S, Sugawara K, Okumura N, Chikazawa N, Kuji N, Umezawa A, Tomita M, Yoshimura Y, Van der Jeught M, Ghimire S, O'Leary T, Lierman S, Deforce D, Chuva de Sousa Lopes S, Heindryckx B, De Sutter P, Herrero J, Tejera A, De los Santos MJ, Castello D, Romero JL, Meseguer M, Barriere P, Lammers J, Lattes S, Leperlier F, Mirallie S, Jean M, Freour T, Schats R, Al-Nofal M, Vergouw CG, Lens JW, Rooth H, Kostelijk EH, Hompes PG, Lambalk CB, Hreinsson J, Karlstrom PO, Wanggren K, Lundqvist M, Vahabi Z, Eftekhari-Yazdi P, Dalman A, Ebrahimi B, Daneshzadeh MT, Rajabpour Niknam M, Choi EG, Rho YH, Oh DS, Park LS, Cheon HS, Lee CS, Kong IK, Lee SC, Liebenthron J, Montag M, Koster M, Toth B, Reinsberg J, van der Ven H, Strowitzki T, Morita H, Hirosawa T, Watanabe S, Wada T, Kamihata M, Kuwahata A, Ochi M, Horiuchi T, Fatemeh H, Eftekhari-Yazdi P, Karimian L, Fazel M, Fouladi H, Johansson L, Ruttanajit T, Chanchamroen S, Sopaboon P, Seweewanlop S, Sawakwongpra K, Jindasri P, Jantanalapruek T, Charoonchip K, Vajta G, Quangkananurug W, Yi G, Jo JW, Jee BC, Suh CS, Kim SH, Zhang Y, Zhao HJ, Cui YG, Gao C, Gao LL, Liu JY, Sozen E, Buluc B, Vicdan K, Akarsu C, Tuncay G, Hambiliki F, Bungum M, Agapitou K, Makrakis E, Liarmakopoulou S, Anagnostopoulou C, Moustakarias T, Giannaris D, Wang J, Andonov M, Linara E, Charleson C, Ahuja KK, Ozsoy S, Morris MB, Day ML, Cobo A, Castello D, Viloria T, Campos P, Vallejo B, Remohi J, Roldan M, Perez-Cano I, Cruz M, Martinez M, Gadea B, Munoz M, Garrido N, Meseguer M, Mesut N, Ciray HN, Mesut A, Isler A, Bahceci M, Munoz M, Fortuno S, Legidos V, Muela L, Roldan M, Galindo N, Cruz M, Meseguer M, Gunasheela S, Gunasheela D, Ueno S, Uchiyama K, Kondo M, Ito M, Kato K, Takehara Y, Kato O, Edgar DH, Krapez JA, Bacer Kermavner L, Virant-Klun I, Pinter B, Tomazevic T, Vrtacnik-Bokal E, Lee SG, Kang SM, Lee SW, Jeong HJ, Lee YC, Lim JH, Bochev I, Valkova L, Kyurkchiev S, Shterev A, Wilding M, Coppola G, Di Matteo L, Dale B, Hormann-Kropfl M, Kastelic D, Montag M, Schenk M, Fourati Ben Mustapha S, Khrouf M, Braham M, Kallel L, Elloumi H, Merdassi G, Chaker A, Ben Meftah M, Zhioua F, Zhioua A, Kocent J, Neri QV, Rosenwaks Z, Palermo GD, Best L, Campbell A, Fishel S, Calimlioglu N, Sahin G, Akdogan A, Susamci T, Bilgin M, Goker ENT, Tavmergen E, Cantatore C, Ding J, Depalo R, Smith GD, Kasapi E, Panagiotidis Y, Papatheodorou A, Goudakou M, Pasadaki T, Nikolettos N, Asimakopoulos B, Prapas Y, Soydan E, Gulebenzer G, Karatekelioglu E, Budak E, Pehlivan Budak T, Alegretti J, Cuzzi J, Negrao PM, Moraes MP, Bueno MB, Serafini P, Motta ELA, Elaimi A, Harper JC, Stecher A, Baborova P, Wirleitner B, Schwerda D, Vanderzwalmen P, Zech NH, Stanic P, Hlavati V, Gelo N, Pavicic-Baldani D, Sprem-Goldstajn M, Radakovic B, Kasum M, Strelec M, Simunic V, Vrcic H, Khan I, Urich M, Abozaid T, Ullah K, Abuzeid M, Fakih M, Shamma N, Ayers J, Ashraf M, Milik S, Pirkevi C, Atayurt Z, Yazici S, Yelke H, Kahraman S, Dal Canto M, Coticchio G, Brambillasca F, Mignini Renzini M, Novara P, Maragno L, Karagouga G, De Ponti E, Fadini R, Resta S, Magli MC, Cavallini G, Muzzonigro F, Ferraretti AP, Gianaroli L, Barberi M, Orlando G, Sciajno R, Serrao L, Fava L, Preti S, Bonu MA, Borini A, Varras M, Polonifi A, Mantzourani M, Mavrogianni D, Stefanidis K, Griva T, Bletsa R, Dinopoulou V, Drakakis P, Loutradis D, Campbell A, Hickman CFL, Duffy S, Bowman N, Gardner K, Fishel S, Sati L, Zeiss C, Demir R, McGrath J, Yelke H, Atayurt Z, Yildiz S, Unal S, Kumtepe Y, Kahraman S, Atayurt Z, Yelke H, Unal S, Kumtepe Y, Kahraman S, Aljaser F, Hernandez J, Tomlinson M, Campbell B, Fosas N, Redondo Ania M, Marina F, Molfino F, Martin P, Perez N, Carrasco A, Garcia N, Gonzalez S, Marina S, Redondo Ania M, Marina F, Molfino F, Fosas N, Martin P, Perez N, Carrasco A, Garcia N, Gonzalez S, Marina S, Scaruffi P, Stigliani S, Tonini GP, Venturini PL, Anserini P, Guglielmo MC, Coticchio G, Albertini DF, Dal Canto M, Brambillasca F, Lain M, Caliari I, Mignini Renzini M, Fadini R, Oikonomou Z, Chatzimeletiou K, Sioga A, Oikonomou L, Kolibianakis E, Tarlatzis B, Nottola SA, Bianchi V, Lorenzo C, Maione M, Macchiarelli G, Borini A, Gomez E, Gil MA, Sanchez-Osorio J, Maside C, Martinez MJ, Torres I, Rodenas C, Cuello C, Parrilla I, Molina G, Garcia A, Margineda J, Navarro S, Roca J, Martinez EA, Avcil F, Ozden H, Candan ZN, Uslu H, Karaman Y, Gioacchini G, Giorgini E, Carnevali O, Bianchi V, Ferraris P, Vaccari L, Borini A, Choe S, Tae J, Kim C, Lee J, Hwang D, Kim K, Suh C, Jee B, Ozden H, Candan ZN, Avcil F, Uslu H, Karaman Y, Catt SL, Sorenson H, Vela M, Duric V, Chen P, Temple-Smith PD, Pangestu M, Yoshimura T, Fukunaga N, Nagai R, Kitasaka H, Tamura F, Hasegawa N, Kato M, Nakayama K, Takeuchi M, Aoyagi N, Yasue K, Watanabe H, Asano E, Hashiba Y, Asada Y, Iwata K, Yumoto K, Mizoguchi C, Sargent H, Kai Y, Ueda M, Tsuchie Y, Imajo A, Iba Y, Mio Y, Els-Smit CL, Botha MH, Sousa M, Windt-De Beer M, Kruger TF, Muller N, Magli C, Corani G, Giusti A, Castelletti E, Gambardella L, Gianaroli L, Seshadri S, Sunkara SK, El-Toukhy T, Kishi I, Maruyama T, Ohishi M, Akiba Y, Asada H, Konishi Y, Nakano M, Kamei K, Yoshimura Y, Lee JH, Lee KH, Park IH, Sun HG, Kim SG, Kim YY, Choi EM, Lee DH, Chavez SL, Loewke KE, Behr B, Han J, Moussavi F, Reijo Pera RA, Yokota H, Yokota Y, Yokota M, Sato S, Nakagawa M, Sato M, Anazawa I, Araki Y, Virant-Klun I, Knez K, Pozlep B, Tomazevic T, Vrtacnik-Bokal E, Lim JH, Vermilyea MD, Graham JR, Levy MJ, Tucker MJ, Carvalho M, Cordeiro I, Leal F, Aguiar A, Nunes J, Rodrigues C, Soares AP, Sousa S, Calhaz-Jorge C, Braga DPAF, Setti AS, Figueira RCS, Aoki T, Iaconelli A, Borges E, Ozkavukcu S, Sonmezer M, Atabekoglu C, Berker B, Ozmen B, Isbacar S, Ibis E, Menezes J, Lalitkumar PGL, Borg P, Ekwurtzel E, Nordqvist S, Vaegter K, Tristen C, Sjoblom P, Azevedo MC, Figueira RCS, Braga DPAF, Setti AS, Iaconelli A, Borges E, Remohi Gimenez J, Cobo A, Castello D, Gamiz P, Albert C, Ferreira RC, Braga DPAF, Figueira RCS, Setti AS, Resende S, Iaconelli A, Borges E, Colturato SS, Braga DPAF, Figueira RCS, Setti AS, Resende S, Iaconelli A, Borges E, Ferrer Buitrago M, Ferrer Robles E, Munoz Soriano P, Ruiz-Jorro M, Calatayud Lliso C, Rawe VY, Wanggren K, Hanrieder J, Hambiliki F, Gulen-Yaldir F, Bergquist J, Stavreus-Evers A, Hreinsson J, Grunskis A, Bazarova A, Dundure I, Fodina V, Brikune J, Lakutins J, Pribenszky C, Cornea M, Reichart A, Uhereczky G, Losonczy E, Ficsor L, Lang Z, Ohgi S, Nakamura C, Hagiwara C, Kawashima M, Yanaihara A, Jones GM, Biba M, Kokkali G, Vaxevanoglou T, Chronopoulou M, Petroutsou K, Sfakianoudis K, Pantos K, Perez-Cano I, Gadea B, Martinez M, Muela L, Cruz M, Galindo N, Munoz M, Garrido N, Romano S, Albricci L, Stoppa M, Cerza C, Sanges F, Fusco S, Capalbo A, Maggiulli R, Ubaldi F, Rienzi L, Ulrick J, Kilani S, Chapman M, Losada C, Ortega I, Pacheco A, Bronet F, Aguilar J, Ojeda M, Taboas E, Perez M, Munoz E, Pellicer A, Meseguer M, Boumela I, Assou S, Haouzi D, Monzo C, Dechaud H, Hamamah S, Dechaud H, Boumela I, Assou S, Haouzi D, Monzo C, Hamamah S, Nakaoka Y, Hashimoto S, Amo A, Yamagata K, Nakano T, Akamatsu Y, Mezawa T, Ohnishi Y, Himeno T, Inoue T, Ito K, Morimoto Y. EMBRYOLOGY. Hum Reprod 2012. [DOI: 10.1093/humrep/27.s2.77] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Sohn BS, Yoon DH, Kim S, Lee K, Kang EH, Park JS, Lee DH, Kim SH, Huh J, Suh C. The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience. Eur J Clin Microbiol Infect Dis 2011; 31:1653-61. [DOI: 10.1007/s10096-011-1489-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Accepted: 11/05/2011] [Indexed: 10/15/2022]
|
49
|
Kim Y, Kim S, Kim J, Cho J, Chang J, Kim D, Lee K, Suh C. MGMT Gene Promoter Methylation Status as a Potent Prognostic Factor in Glioblastoma Treated with Temozolomide Chemo-irradiation. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
50
|
Colakoglu M, Toy H, Icen MS, Vural M, Mahmoud AS, Yazici F, Buendgen N, Cordes T, Schultze-Mosgau A, Diedrich K, Beyer D, Griesinger G, Oude Loohuis EJ, Nahuis MJ, Bayram N, Hompes PGA, Oosterhuis GJE, Bossuyt PM, van der Veen F, Mol BWJ, van Wely M, Nahuis MJ, Oude Loohuis EJ, Kose N, Bayram N, Hompes PGA, Oosterhuis GJE, Bossuyt PM, van der Veen F, Mol BWJ, van Wely M, Yaba A, Demir N, Allegra A, Pane A, Marino A, Scaglione P, Ruvolo G, Manno M, Volpes A, Lunger F, Wildt L, Seeber B, Kolibianakis EM, Venetis CA, Bosdou J, Toulis K, Goulis DG, Tarlatzi TB, Tarlatzis BC, Franz M, Keck C, Daube S, Pietrowski D, Demir N, Yaba A, Iannetta R, Santos RDS, Lima TP, Giolo F, Iannetta O, Martins WP, Paula FJ, Ferriani RA, Rosa e Silva ACJS, Martinelli CE, Reis RM, Devesa M, Rodriguez I, Coroleu B, Tur R, Gonzalez C, Barri PN, Nardo LG, Mohiyiddeen L, Mulugeta B, McBurney H, Roberts SA, Newman WG, Grynberg M, Lamazou F, Even M, Gallot V, Frydman R, Fanchin R, Abdalla H, Nicopoullos J, Leader A, Pang S, Witjes H, Gordon K, Devroey P, Arrivi C, Ferraretti AP, Magli MC, Tartaglia ML, Fasolino MC, Gianaroli L, Macek sr. M, Feldmar P, Kluckova H, Hrehorcak M, Diblik J, Cernikova J, Paulasova P, Turnovec M, Macek jr. M, Hillensjo T, Yeko T, Witjes H, Elbers J, Devroey P, Mardesic T, Abuzeid M, Witjes H, Mannaerts B, Okubo T, Matsuo R, Kuwayama M, Teramoto S, Chakraborty P, Goswami SK, Chakravarty BN, Nandi SS, Kabir SN, Ramos Vidal J, Prados N, Caligara C, Garcia J, Carranza FJ, Gonzalez-Ravina A, Salazar A, Tocino A, Rodriguez I, Fernandez-Sanchez M, Ito H, Iwasa T, Hasegawa E, Hatano K, Nakayama D, Kazuka M, Usuda S, Isaka K, Ventura V, Doria S, Fernandes S, Barros A, Valkenburg O, Lao O, Schipper I, Louwers YV, Uitterlinden AG, Kayser M, Laven JSE, Sharma S, Goswami S, Goswami SK, Ghosh S, Chattopadhyay R, Sarkar A, Chakravarty BN, Louwers YV, Valkenburg O, Lie Fong S, van Dorp W, de Jong FH, Laven JSE, Ghosh S, Chattopadhyay R, Goswami SK, Radhika KL, Chakravarty BN, Benkhalifa M, Demirol A, Montjeant D, Delagrange P, Gentien D, Giakoumakis G, Menezo Y, Dattilo M, Gurgan T, Engels S, Blockeel C, Haentjens P, De Vos M, Camus M, Devroey P, Dimitraki M, Koutlaki N, Gioka T, Messini CI, Dafopoulos K, Messinis IE, Gurlek B, Batioglu S, Ozyer S, Nafiye Y, Kale I, Karayalcin R, Uncu G, Kasapoglu I, Uncu Y, Celik N, Ozerkan K, Ata B, Ferrero H, Gomez R, Delgado F, Simon C, Gaytan F, Pellicer A, Osborn JC, Fien L, Wolyncevic J, Esler JH, Choi D, Kim N, Choi J, Jo M, Lee E, Lee D, Fujii R, Neyatani N, Waseda T, Oka Y, Takagi H, Tomizawa H, Sasagawa T, Makinoda S, Ajina M, Zorgati H, Ben Salem A, Ben Ali H, Mehri S, Touhami M, Saad A, Piouka A, Karkanaki A, Katsikis I, Delkos D, Mousatat T, Daskalopoulos G, Panidis D, Pantos K, Stavrou D, Sfakianoudis K, Angeli E, Chronopoulou M, Vaxevanoglou T, Jones R GMJ, Lee WD, Kim SD, Jee BC, Kim KC, Kim KH, Kim SH, Kim YJ, Park KA, Chae SJ, Lim KS, Hur CY, Kang YJ, Lee WD, Lim JH, Tomizawa H, Makinoda S, Fujita S, Waseda T, Fujii R, Utsunomiya R T, Vieira C, Martins WP, Fernandes JBF, Soares GM, Reis RM, Silva de Sa MF, Ferriani R RA, Yoo JH, Kim HO, Cha SH, Koong MK, Song IO, Kang IS, Hatakeyama N, Jinno M, Watanabe A, Hirohama J, Hiura R, Konig TE, Beemsterboer SN, Overbeek A, Hendriks ML, Heymans MW, Hompes P, Homburg R, Schats R, Lambalk CB, van der Houwen L, Konig TE, Overbeek A, Hendriks ML, Beemsterboer SN, Kuchenbecker WK, Renckens CNM, Bernardus RE, Schats R, Homburg R, Hompes P, Lambalk CB, Potdar N, Gelbaya TA, Nardo LG, de Groot PCM, Dekkers OM, Romijn JA, Dieben SWM, Helmerhorst FM, Guivarch Leveque A, Homer L, Broux PL, Moy L, Priou G, Vialard J, Colleu D, Arvis P, Dewailly D, Aghahosseini M, Aleyasin A, Sarvi F, Safdarian L, Rahmanpour H, Akhtar MA, Navaratnam K, Ankers D, Sharma SD, Son WY, Chung JT, Reinblatt S, Dahan M, Demirtas M, Holzer H, Aspichueta F, Exposito A, Crisol L, Prieto B, Mendoza R, Matorras R, Kim K, Lee J, Jee B, Lee W, Suh C, Moon J, Kim S, Sarapik A, Velthut A, Haller-Kikkatalo K, Faure GC, Bene MC, de Carvalho M, Massin F, Uibo R, Salumets A, Alhalabi M, Samawi S, Taha A, Kafri N, Modi S, Khatib A, Sharif J, Othman A, Hamamah S, Assou S, Anahory T, Loup V, Dechaud H, Dewailly D, Mousavi Fatemi H, Doody K, Witjes H, Mannaerts B, Basconi V, Jungblut L, Young E, Van Thillo G, Paz D, Pustovrh MC, Fabbri R, Pasquinelli G, Magnani V, Macciocca M, Parazza I, Battaglia C, Paradisi R, Venturoli S, Ono M, Teranisi A, Fumino T, Ohama N, Hamai H, Chikawa A, Takata R, Teramura S, Iwahasi K, Shigeta M, Heidari M, Farahpour M, Talebi S, Edalatkhah H, Zarnani AH, Ardekani AM, Pietrowski D, Szabo L, Sator M, Just A, Franz M, Egarter C, Hope N, Motteram C, Rombauts LJ, Lee W, Chang E, Han J, Won H, Yoon T, Seok H, Diao FY, Mao YD, Wang W, Ding W, Liu JY, Chang E, Yoon T, Lee W, Cho J, Kwak I, Kim Y, Afshan I, Cartwright R, Trew G, Lavery S, Lockwood G, Niyani K, Banerjee S, Chambers A, Pados G, Tsolakidis D, Billi H, Athanatos D, Tarlatzis B, Salumets A, Laanpere M, Altmae S, Kaart T, Stavreus-Evers A, Nilsson TK, van Dulmen-den Broeder E, van der Stroom E, Konig TE, van Montfrans J, Overbeek A, van den Berg MH, van Leeuwen FE, Lambalk CB, Taketani T, Tamura H, Tamura I, Asada H, Sugino N, Al - Azemi M, Kyrou D, Papanikolaou EG, Polyzos NP, Devroey P, Fatemi HM, Qiu Z, Yang L, Yan G, Sun H, Hu Y, Mohiyiddeen L, Higgs J, Roberts S, Newman W, Nardo LG, Ho C, Guijarro JA, Nunez R, Alonso J, Garcia A, Cordeo C, Cortes S, Caballero P, Soliman S, Baydoun R, Wang B, Shreeve N, Cagampang F, Sadek K, Hill CM, Brook N, Macklon N, Cheong Y, Santana R, Setti AS, Maldonado LG, Valente FM, Iaconelli C, Braga DPAF, Iaconelli Jr. A, Borges Jr. E, Yoon JS, Won MY, Kim SD, Jung JH, Yang SH, Lim JH, Kavrut M, Kahraman S, Sadek KH, Bruce KB, Macklon N, Cagampang FR, Cheong YC, Cota AMM, Oliveira JBA, Petersen CG, Mauri AL, Massaro FC, Silva LFI, Vagnini LD, Nicoletti A, Pontes A, Cavagna M, Baruffi RLR, Franco Jr. JG, Won MY, Kim SD, Yoon JS, Jung JH, Yang SH, Lim JH, Kim SD, Kim JW, Yoon TK, Lee WS, Han JE, Lyu SW, Shim SH, Kuwabara Y, Katayama A, Tomiyama R, Piao H, Ono S, Shibui Y, Abe T, Ichikawa T, Mine K, Akira S, Takeshita T, Hatzi E, Lazaros L, Xita N, Kaponis A, Makrydimas G, Sofikitis N, Stefos T, Zikopoulos K, Georgiou I, Guimera M, Casals G, Fabregues F, Estanyol JM, Balasch J, Mochtar MH, Van den Wijngaard L, Van Voorst S, Koks CAM, Van Mello NM, Mol BWJ, Van der Veen F, Van Wely M, Fabregues F, Iraola A, Casals G, Creus M, Carmona F, Balasch J, Villarroel C, Lopez P, Merino P, Iniguez G, Codner E, Xu B, Cui Y, Gao L, Xue KAI, Li MEI, Zhang YUAN, Diao F, Ma X, Liu J, Leonhardt H, Gull B, Kishimoto K, Kataoka M, Stener-Victorin E, Hellstrom M, Cui Y, Wang X, Zhang Z, Ding G, HU X, Sha J, Zhou Z, Liu J, Liu J, Kyrou D, Kolibianakis EM, Fatemi HM, Camus M, Tournaye H, Tarlatzis BC, Devroey P, Davari F, Rashidi B, Rahmanpour Zanjani H, Al-Inany H, Youssef M, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abousetta A, Van Dessel H, Van Leeuwen J, McGee EA, Bodri D, Guillen JJ, Rodriguez A, Trullenque M, Coll O, Vernaeve V, Snajderova M, Keslova P, Sedlacek P, Formankova R, Kotaska K, Stary J, Weghofer A, Dietrich W, Barad DH, Gleicher N, Rustamov O, Pemberton P, Roberts S, Smith A, Yates A, Patchava S, Nardo L, Toulis KA, Mintziori G, Goulis DG, Kintiraki E, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergianos S, Poulasouhidou M, Tzellos TG, Tarlatzis BC, Nasiri R, Ramezanzadeh F, Sarafraz Yazdi M, Baghrei M, Lee RKK, Wu FS, Lin S, Lin MH, Hwu YM. POSTER VIEWING SESSION - REPRODUCTIVE ENDOCRINOLOGY. Hum Reprod 2011. [DOI: 10.1093/humrep/26.s1.90] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|